DHR earnings analysis
What we found in DHR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Danaher delivered Q2 revenue of $6.265 billion, up 5.5% year over year and 5.3% sequentially, supported by broad Life Sciences and Biotechnology growth and the Masimo acquisition. GAAP EPS increased to $1.23 from $0.77 a year ago, though the comparison was substantially aided by the prior-year $432 million impairment, while gross margin fell to 57.6% and operating margin was down sharply sequentially to 18.0%. Cash generation remained strong, with $2.856 billion of first-half operating cash flow, but the $9.8 billion Masimo acquisition raised debt and created near-term Diagnostics margin dilution.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth accelerated to 5.5%
- Q2 revenue rose 5.5% year over year to $6.265 billion and 5.3% sequentially from $5.950 billion in Q1 2026. Core sales grew 3.0%, or 4.5% excluding respiratory testing; acquisitions and FX added 1.5% and 1.0%, respectively, to reported growth.
- Life Sciences and Biotechnology grew
- Life Sciences was the strongest reported-growth segment, with sales up 5.5% to $1.879 billion and core sales up 5.5%. Biotechnology sales rose 4.0% to $1.920 billion, with consumables demand leading growth.
- Diagnostics underlying demand improved
- Diagnostics sales increased 7.0% to $2.466 billion, including a 4.0% acquisition contribution from Masimo. Underlying Diagnostics core sales excluding respiratory testing rose 5.0%, despite a 1.5% price headwind.
- Year-over-year earnings recovered
- GAAP operating margin improved 520 basis points year over year to 18.0%, while diluted EPS increased to $1.23 from $0.77. The comparison benefited from a $432 million Life Sciences trade-name impairment recorded in Q2 2025.
- Operating cash flow increased 8%
- First-half operating cash flow increased 8% to $2.856 billion. After $506 million of capital expenditures, six-month free cash flow was approximately $2.350 billion, equal to 17.3% of $13.6 billion first-half sales.
- Masimo expands Diagnostics portfolio
- Danaher completed the $9.8 billion cash acquisition of Masimo on June 10, 2026; Masimo generated approximately $1.5 billion of 2025 revenue. The deal expands Diagnostics into patient-monitoring technologies and acute-care settings.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Gross margin compressed on acquisition mix
- Gross margin declined 170 basis points year over year to 57.6% and 270 basis points sequentially from 60.3%. A $46 million Masimo inventory fair-value adjustment contributed to higher cost of sales.
- Diagnostics margin dilution remains material
- Diagnostics operating margin fell 710 basis points year over year to 16.9%. Masimo-related inventory adjustments, transaction costs, and pre-acquisition share-based/change-in-control payments accounted for 440 basis points of the decline.
- New conflict and financing-risk disclosure
- The filing adds 1 new risk factor covering military conflicts. While no material operational interruption occurred in the first half of 2026, management cited delivery delays and higher logistics costs in the Middle East; it also recorded $107 million of Q2 interest expense, up $36 million year over year following higher borrowings.
- Respiratory testing remains volatile
- Reported Diagnostics core sales grew 2.0%, but molecular-diagnostics respiratory-test demand declined as the first-half 2026 respiratory season was less severe. Management says the severity of the upcoming season and customer purchases could adversely affect demand through the remainder of 2026.
- Acquisition financing increased borrowing
- Masimo financing increased leverage: the company issued $6.555 billion of long-term debt and generated $3.673 billion of net short-term borrowings in the first half, while repaying $1.434 billion of long-term debt. Cash and equivalents stood at approximately $4.3 billion at June 26, 2026.
- China pricing pressure constrains growth
- High-growth markets represented approximately 31% of Q2 sales, but China pricing pressure persists. Diagnostics prices declined 1.5%, primarily from China's volume-based procurement program and sales promotions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.23
- Gross margin
- 57.6%
- Operating margin
- 18.0%
- Segment
- Biotechnology: $1.920 billion revenue, up 4.0% year over year
- Segment
- Life Sciences: $1.879 billion revenue, up 5.5% year over year
- Segment
- Diagnostics: $2.466 billion revenue, up 7.0% year over year
What they said about what is next.
The 10-Q provides no quantitative revenue or EPS outlook. Management expects an approximately 17.0% effective tax rate for the remainder of 2026, based on projected earnings mix; actual results may vary with stock-compensation tax benefits, geographic mix, discrete tax items, and tax-law changes.
The filing reads about the same as the one before it.
What came before.
- 10-Q · April 20, 2026
- Danaher reported Q1 sales of $5,951 million, up $210 million (+3.7%) versus the year-ago quarter but down $889 million (-13.0%) sequentially. Gross profit was $3,591 million (gross margin ~60.35%) with operating profit…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DHR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever